D. Isla

A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)

Luis Paz‐Ares, J. M. Sanchez, A. García et al. · Journal of Clinical Oncology · 2006 · 162 citations

Medicine, Oncology, Pharmacology +17

Apolipoprotein C-III and E Polymorphisms and Cardiovascular Syndrome, Hyperlipidemia, and Insulin Resistance in Renal Transplantation

Emilio Rodrigo, Domingo González‐Lamuño, Juan Carlos Ruiz et al. · American Journal of Transplantation · 2002 · 18 citations

Medicine, Genetics, Nephrology +16

High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)

Teresa Morán, Luis Paz‐Ares, D. Isla et al. · Journal of Clinical Oncology · 2007 · 13 citations

Medicine, Genetics, Oncology +16

Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

R. Porta, Cristina Queralt, F. Cardenal et al. · Journal of Clinical Oncology · 2008 · 10 citations

Medicine, Oncology, Pharmacology +17